Stock market today: S&P 500 rides Apple-led tech rally to close higher
Evolus Inc (NASDAQ:EOLS) stock has reached a 52-week low, touching down at $9.22, as the company faces a challenging market environment. According to InvestingPro data, the stock's RSI indicates oversold conditions, while the company maintains strong revenue growth of ~32% in the last twelve months. This latest price point marks a significant downturn for the aesthetic medicine company, which has seen its shares struggle over the past year. The 1-year change data for Evolus Inc reveals a substantial decline of 27.49%, reflecting investor concerns and possibly internal hurdles that the company has yet to overcome. Despite the current challenges, analysts maintain optimistic price targets ranging from $20 to $27, and InvestingPro's analysis indicates the stock is currently undervalued. As shareholders and potential investors consider this new low, the broader implications for the company's financial health and future prospects are likely to come under close scrutiny. The company maintains a healthy current ratio of 2.4, with InvestingPro's Financial Health Score indicating GOOD overall condition. Discover more insights and 8 additional ProTips with a subscription to InvestingPro.
In other recent news, Evolus announced its fourth-quarter 2024 financial results, reporting revenues of $79 million, which aligned with consensus estimates and marked a 30% year-over-year increase. For the full year, the company achieved $266.3 million in revenue, representing a 32% rise compared to the previous year. Despite missing earnings per share (EPS) expectations with a reported EPS of -$0.11 against the forecasted $0.02, the company surpassed revenue expectations, indicating robust sales performance. Evolus has projected 2025 revenues between $345 million to $355 million, reflecting anticipated growth of 30% to 33%, driven by the early approval and expected contribution of new products, Evolysse SMOOTH and FORM.
Analysts at Stifel and H.C. Wainwright have maintained their Buy ratings on Evolus, with price targets set at $25 and $27, respectively. These ratings are supported by Evolus's strong market penetration and product launches, which are expected to enhance both new account growth and product penetration. The company's achievement of full-year profitability ahead of schedule and its optimistic guidance for 2025 further bolster analyst confidence. Evolus has also seen significant engagement with its loyalty programs, surpassing 1.1 million participants, which contributes to its strong market position in the U.S. aesthetic toxin category.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.